Open an account

Nuvation Bio

NUVB · NYSE

$4.77+$0.29 (+6.47%)TodayMarket closed ·
Prev close $4.48

About NUVB

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Employees
298
Headquarters
New York City, New York
Listed
Jul 1, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
nuvationbio.com

NUVB key statistics

Market cap
1.68B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.49M
Volume
6.85M
Open price
$4.51
High today
$4.82
Low today
$4.46
52 Week high
$9.75
52 Week low
$3.45

Nuvation Bio (NUVB) at a glance

Nuvation Bio (NUVB) last traded at $4.77, with a market cap of 1.68B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.46 and $4.82. The current price is 7.0% above the day's low and 1.0% below its high.

Volume so far is 6.85M shares, above the average of 5.49M shares a day.

Over the past year Nuvation Bio has ranged from $3.45 to $9.75, and now sits 21% of the way up that range.

Nuvation Bio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.15 per share against an estimate of -$0.1888.

The average analyst price target is $13.57, 184.4% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

91%of 11 analyst ratings say Buy
  • Buy90.9%
  • Hold9.1%
  • Sell0.0%
Price target · 12 analystsAvg $13.57
Low
$7.07
Now
$4.77
High
$22.05

NUVB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 7.6% on average.

  1. Q3 FY24: reported -$0.15 per share against an estimate of -$0.1326
  2. Q4 FY24: reported -$0.15 per share against an estimate of -$0.1408
  3. Q1 FY25: reported -$0.16 per share against an estimate of -$0.1615
  4. Q2 FY25: reported -$0.17 per share against an estimate of -$0.1715
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.172
  6. Q4 FY25: reported -$0.11 per share against an estimate of -$0.0911
  7. Q1 FY26: reported $0.01 per share against an estimate of $0.0092
  8. Q2 FY26: reported -$0.15 per share against an estimate of -$0.1888

NUVB news

  • Vandana Singh

    Why Is Nuvation Bio Stock Gaining Thursday?

  • Press releasePRNewswire

    Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

  • Press releasePRNewswire

    Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

  • Avi Kapoor

    Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...

  • Press releasePRNewswire

    Nuvation Bio to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

  • Press releasePRNewswire

    Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Similar companies

Companies in the same industry as Nuvation Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.